Salemonline Journal

Peanut Allergy Pipeline | 15+ Companies & 15+ Drugs | DelveInsight

 Breaking News
  • No posts were found

Peanut Allergy Pipeline | 15+ Companies & 15+ Drugs | DelveInsight

November 24
22:24 2022
Peanut Allergy Pipeline | 15+ Companies & 15+ Drugs | DelveInsight

DelveInsight’s, “Peanut Allergy Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Peanut Allergy Pipeline

  • DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. It is currently in preregistration stage of development.
  • Dupilumab is a IL-4R Antibody that is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of Peanut Allergy. It is currently in phase II stage of development.
  • CNP-201 is a biodegradable nanoparticle encapsulating peanut protein. It has the potential to treat patients with peanut allergy by reducing the need for strict peanut avoidance and reducing the potentially fatal health risks associated with peanut allergy. It is currently in phase I/II stage of development.

 

Key takeaways from the Peanut Allergy Pipeline Report

  • DelveInsight’s Peanut Allergy Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Peanut Allergy treatment.
  • The leading Peanut Allergy Companies are working such as DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
  • Promising Peanut Allergy Pipeline therapies such as pnt ASIT+, VLP Peanut, HAL-MPE1, INT301, INP20, CNP-201, VE416, Dupilumab, Acalabrutinib, CA002, Omalizumab, and others
  • The Peanut Allergy Companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Peanut Allergy.

 

Request a sample and discover the recent breakthroughs happening Peanut Allergy pipeline landscape @ Peanut Allergy Pipeline Outlook

 

Peanut Allergy Overview

A peanut allergy is a reaction that occurs when your body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system —the body’s natural defense system that fights infections and diseases—overreacts and can cause a serious, even life-threatening response. Symptoms of peanut allergy can range from mild to severe. If you have a mild reaction, you may get a stomachache, a runny nose, itchy eyes, hives, or tingling in your lips or tongue. Your symptoms may start from within a few minutes to a few hours after eating peanuts or peanut products.

 

Peanut Allergy Pipeline Insight Report

The Peanut Allergy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Peanut Allergy Emerging Drugs

  • Viaskin Peanut: DBV Technologies
  • Dupilumab: Regeneron Pharmaceuticals/Sanofi
  • CNP-201: Cour Pharmaceutical

 

Dive deep into rich insights for Peanut Allergy drug in the pipeline, visit @ Peanut Allergy Treatment Landscape

 

Peanut Allergy Pipeline Therapeutics Analysis

There are approx. 15+ key companies which are developing the therapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. preregistration include, DBV Technologies.

 

Scope of the Peanut Allergy Pipeline Report

  • Coverage- Global
  • Peanut Allergy Companies- DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
  • Peanut Allergy Pipeline therapiesASIT+, VLP Peanut, HAL-MPE1, INT301, INP20, CNP-201, VE416, Dupilumab, Acalabrutinib, CA002, Omalizumab, and others
  • Peanut Allergy Key Companies
  • Peanut Allergy Key Products
  • Peanut Allergy- Unmet Needs

 

Table of Content

  1. Introduction
  2. Peanut Allergy Executive Summary
  3. Peanut Allergy: Overview
  4. Peanut Allergy Pipeline Therapeutics
  5. Peanut Allergy Therapeutic Assessment
  6. Late Stage Products (Preregistration)
  7. Viaskin Peanut: DBV Technologies
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Dupilumab: Regeneron Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I/II)
  13. CNP-201: Cour Pharmaceutical
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Peanut-NE01 vaccine: BlueWillow Biologics
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Peanut Allergy Key Companies
  20. Peanut Allergy Key Products
  21. Peanut Allergy- Unmet Needs
  22. Peanut Allergy- Market Drivers and Barriers
  23. Peanut Allergy- Future Perspectives and Conclusion
  24. Peanut Allergy Analyst Views
  25. Peanut Allergy Key Companies
  26. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Peanut Allergy drugs?
  • How many Peanut Allergy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peanut Allergy and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Peanut Allergy pipeline therapeutics, reach out to Peanut Allergy Clinical Trials

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles